A phase IV study, prospective, randomised, open label, blinded endpoint, parallel group, 9 weeks of comparison between oral administration of telmisartan tablet (80mg once daily) and amlodipine tablet (10 mg once daily) on biological PPAR gamma [peroxisome proliferator-activated receptor gamma] activities in non controlled hypertensive male patients

Trial Profile

A phase IV study, prospective, randomised, open label, blinded endpoint, parallel group, 9 weeks of comparison between oral administration of telmisartan tablet (80mg once daily) and amlodipine tablet (10 mg once daily) on biological PPAR gamma [peroxisome proliferator-activated receptor gamma] activities in non controlled hypertensive male patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2008

At a glance

  • Drugs Amlodipine; Telmisartan
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Nov 2008 Last updated from ClinicalTrials.gov record.
    • 01 Feb 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top